EVO Evotec SE
Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just Evotec Biolog…
Industry Peers
Drug Manufacturers - Specialty & Generic| Headline | Source | Time |
|---|---|---|
Older | ||
 Odyssey Therapeutics (ODTX) Looks Fully Valued As Earnings And Evotec Deal Refocus Attention Why Odyssey Therapeutics Stock Is Back In Focus Odyssey Therapeutics (ODTX) is drawing attention after reporting second quarter 2026 results that showed a larger net loss alongside a sharp change in reported loss per share from continuing operations. For the quarter ended June 30, 2026, Odyssey Therapeutics reported a net loss of US$52.79 million compared with US$41.24 million a year earlier. Basic and diluted loss per share from continuing operations was US$1.74, while the prior year figure... | ||
 Evotec and Odyssey collaborate on AI-enabled R&D The partnership intends to leverage complementary scientific strengths to boost early-stage research and produce new medicines. | ||
 Health Care Roundup: Market Talk Find insight on Hikma Pharmaceuticals, Evotec and more in the latest Market Talks covering health care. | ||
Evotec SE (EVO) Q2 2026 Earnings Call Highlights: Navigating Revenue Declines and Strategic ... Despite a challenging quarter with revenue declines, Evotec SE (EVO) focuses on liquidity growth, strategic partnerships, and cost-saving initiatives to drive future success. | ||
 Evotec Q2 Earnings Call Highlights Evotec (NASDAQ:EVO) reported preliminary unaudited results for the second quarter and first half of 2026 and lowered its full-year outlook, citing delayed strategic partnership revenue, slower conversion of commercial activity into revenue and longer timelines for new partnership agreements. Chief | ||